Figure 4.

Linear regression of the logarithm of the relative tumor size (log(RTS) +/- SD). This method was applied for the initial 30 days' growth and growth delay data analysis. A. The log(RTS) over time for all the therapy groups with ¹⁷⁷Lu-hu11B6. Also included the data previously presented ¹⁸ for the murine antibody 11B6. Both the humanized and murine 11B6 shows similar therapeutic efficacy. Even though no tumor decrease in group A is observed, there is a growth delay compared to the controls (E, F, D). B. The log(RTS) versus tumor absorbed dose, albeit at different dose rates, for all the therapy groups. As can be seen there is almost a linear correlation showing a similar absorbed dose dependent therapeutic efficacy in all groups except in group A. This pattern is recognizable among data from both the humanized, hu11B6 (A, B, G) and the previously published murine (H, I) antibody.